Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature

•In PCNSV there is the need to identify effective therapeutic agents•B-cell depletion in PCNSV maintains disease remission and reduces the number of flares and GC dosage•Rituximab is effective and safe in PCNSV refractory to traditional immunosuppressive agents•Rituximab could  have a role  as a first line therapy for PCNSV patients with less favorable prognosis